Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Acetaminophen | The serum concentration of Acetaminophen can be increased when it is combined with Canertinib. |
| Propacetamol | The serum concentration of Propacetamol can be increased when it is combined with Canertinib. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Canertinib. |
| Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Canertinib. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Canertinib. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Canertinib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Canertinib. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Canertinib. |
| Methimazole | The therapeutic efficacy of Methimazole can be decreased when used in combination with Canertinib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Canertinib. |
| 3,5-Diiodotyrosine | The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Canertinib. |
| Tiratricol | The therapeutic efficacy of Tiratricol can be decreased when used in combination with Canertinib. |
| Parathyroid hormone | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Canertinib. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Canertinib. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Canertinib. |
| Dibromotyrosine | The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Canertinib. |
| Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Canertinib. |
| Potassium perchlorate | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Canertinib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Canertinib. |
| 3,5-diiodothyropropionic acid | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Canertinib. |
| Methylthiouracil | The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Canertinib. |
| Elcatonin | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Canertinib. |
| Benzylthiouracil | The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Canertinib. |
| Thyrotropin | The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Canertinib. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Canertinib. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Canertinib. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Canertinib. |
| Methoxy polyethylene glycol-epoetin beta | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Canertinib. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Quinisocaine. |
| Voriconazole | The serum concentration of Canertinib can be increased when it is combined with Voriconazole. |
| Nelarabine | The risk or severity of adverse effects can be increased when Nelarabine is combined with Canertinib. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Canertinib is combined with Ambroxol. |
| Etrasimod | The risk or severity of immunosuppression can be increased when Canertinib is combined with Etrasimod. |
| Palopegteriparatide | The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Canertinib. |